Translate 
Abstract
The encouraging responses noted in some patients with transitional cell carcinoma of the bladder to cis-platinum based chemotherapy have led to the hope that combination therapy utilizing chemotherapy plus limited surgery may make it possible to preserve the bladder in patients with muscle-invading bladder tumors. Despite the conceptual appeal of a bladder-sparing approach, the effectiveness of combined therapy remains unresolved. At present, there are no data to support the routine use of chemotherapeutic agents combined with surgery in the therapy of bladder cancer. The role of neoadjuvant therapy in the treatment of muscle invasive bladder cancer will only be defined by the results of properly conducted and controlled randomized studies.
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
